Chemistry:Glecaprevir
 | |
| Clinical data | |
|---|---|
| Trade names | Mavyret (combination with pibrentasvir) |
| Other names | ABT-493 |
| Routes of administration | By mouth |
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | 97.5% |
| Metabolism | CYP3A |
| Elimination half-life | 6 hours |
| Excretion | Faeces (92.1%), urine (0.7%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C38H46F4N6O9S |
| Molar mass | 838.87 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glecaprevir (INN,[1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.[2]
On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.[3] In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.[4]
See also
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 76". World Health Organization. p. 503. https://www.who.int/medicines/publications/druginformation/innlists/RL76.pdf.
- ↑ "Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection". Antimicrobial Agents and Chemotherapy 60 (3): 1546–55. December 2015. doi:10.1128/AAC.02264-15. PMID 26711747.
- ↑ "AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C." (in en). AbbVie Inc. North Chicago, Illinois, U.S.A.. December 19, 2016. https://news.abbvie.com/news/abbvie-submits-new-drug-application-to-us-fda-for-its-investigational-regimen-glecaprevirpibrentasvir-gp-for-treatment-all-major-genotypes-chronic-hepatitis-c.htm.
- ↑ "Maviret: EPAR – Summary for the public". European Medicines Agency. 2017-08-17. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004430/WC500233680.pdf.
 |  |
